Optimize Surveillance with Sensitive, Standardized Analytical Assays, Clinically Validated MRD Tests & Reliable ctDNA Surrogate Biomarkers to Detect Disease Earlier & Improve Patient Outcomes
The 2nd Liquid Biopsy Surveillance & Early Detection Summit returned as the industry’s only meeting showcasing biopharma-led case studies and assay developer technical progress in scaling sensitive assays that enable earlier detection and utilizing ctDNA as a surrogate biomarker to improve surveillance for a paradigm shift towards achieving personalized treatment options.
Attendees were able to stay connected and ahead of the curve with unmatched industry insights across key challenges: Sensitivity, Standardizations, Reimbursement, Clinical Utility, Multi-Cancer Early Detection, Clinical Validity, Longitudinal Monitoring
Uniting pharma, biotechs, academics, and diagnostics, this meeting was a unique opportunity to learn about the latest advancements in liquid biopsy detection and early surveillance in oncology, neurology, and rare diseases, and how they can be implemented into clinical trials and in healthy populations.
2023 Speaker Faculty Included
Precision Medicine Global Director
Vice President, Global Head Precision Diagnostics
Bristol Myers Squibb
Hear What Previous Attendees Have to Say…
“The event offered a great opportunity to network and promote my company and its services to advance the study in cancer treatment”
Translational Medicine Scientist, Burning Rock Biotech
“I really enjoyed the fact that we had the first LBx-focused summit here in the Boston area. I enjoyed networking with my fellow ex-colleagues, partners and collaborators”
LBx Strategy Lead, Precision Medicine & CDx, Takeda
“I enjoyed discussing the emerging clinical data and pathways towards clinical implantation for patient benefit”
WW Medical Lead, Bristol Myers Squibb